eNeura is a biotechnology and medical devices startup with a mission to provide effective central neuromodulation therapy for treating acute migraine attacks and preventing future migraine days. Their flagship product, SAVI Dual, utilizes single low frequency electromagnetic fields to signal the brain to calm hyperactive nerves and return to a natural state, a process known as Single Pulse Transcranial Magnetic Stimulation (STMS). The safety of this non-invasive therapy has been well established over decades of clinical practice.
Founded in 2021, eNeura has attracted significant attention from investors, with a recent $5.91M debt financing investment in November 2019. With a focus on revolutionizing migraine treatment, the company has positioned itself at the intersection of healthcare and biotechnology, aiming to make a meaningful impact in the health and wellness industry.
